ASCO Annual Meeting

ASCO Annual Meeting
Name	ASCO Annual Meeting
Genre	Medical conference
Frequency	Annual
First	1964
Organizer	American Society of Clinical Oncology

ASCO Annual Meeting The ASCO Annual Meeting is the principal annual clinical oncology conference organized by the American Society of Clinical Oncology. It convenes oncologists, researchers, patient advocates, and industry representatives from institutions such as Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute and MD Anderson Cancer Center to present clinical trials, translational research, and practice-changing data. The meeting frequently overlaps with regulatory actions by agencies like the Food and Drug Administration and guideline updates from societies such as the National Comprehensive Cancer Network and European Society for Medical Oncology.

Overview

The meeting is hosted by the American Society of Clinical Oncology and typically held in major venues in the United States, with past sites including Chicago, San Francisco, Atlanta, Boston, and Orlando. Program components feature plenary sessions, oral abstracts, poster sessions, roundtables, and industry-sponsored symposia that involve contributors from National Institutes of Health, European Organisation for Research and Treatment of Cancer, Susan G. Komen, Lance Armstrong Foundation, and major pharmaceutical companies like Roche, Novartis, Pfizer, Merck & Co., Bristol Myers Squibb, and AstraZeneca. Attendees include investigators from research centers such as Johns Hopkins Hospital, UCLA Medical Center, Cleveland Clinic, Massachusetts General Hospital, and academic departments at Harvard Medical School and Stanford University School of Medicine.

History and Development

The meeting traces its origins to the founding of the American Society of Clinical Oncology in 1964, evolving alongside landmark developments like the introduction of cytotoxic chemotherapy regimens at centers like MD Anderson Cancer Center and the later emergence of targeted therapies developed at institutions such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. Historical milestones presented at the meeting have paralleled approvals by the Food and Drug Administration for agents from companies like Genentech and GlaxoSmithKline and guideline shifts by organizations such as the National Comprehensive Cancer Network and American Cancer Society. The meeting has reflected global collaboration involving groups such as European Society for Medical Oncology, Japanese Society of Medical Oncology, World Health Organization, and cooperative groups including SWOG and EORTC.

Organization and Program

Program planning is overseen by committees composed of representatives from academic centers including Yale School of Medicine, Columbia University Irving Medical Center, and University of Pennsylvania Perelman School of Medicine. Session types range from plenaries featuring investigators affiliated with Stanford University School of Medicine to poster discussions with contributors from institutions like University of Texas MD Anderson Cancer Center and Fred Hutchinson Cancer Research Center. The meeting includes tracks on solid tumors, hematologic malignancies, precision oncology, and survivorship with participation from advocacy groups such as American Association for Cancer Research and Live Strong Foundation. Industry satellite symposia frequently present data sponsored by firms like Eli Lilly and Company and Amgen, while regulatory panels sometimes include representatives from the Food and Drug Administration and payer organizations.

Scientific Impact and Publications

Data presented often lead to publications in high-impact journals such as The New England Journal of Medicine, The Lancet Oncology, Journal of Clinical Oncology, Nature Medicine, and Science Translational Medicine. Breakthrough abstracts have driven updates to practice guidelines from the National Comprehensive Cancer Network and informed reimbursement decisions by insurers and health technology assessment bodies like NICE. The meeting has accelerated translational work linked to laboratories at Cold Spring Harbor Laboratory, Salk Institute, and university cores at University of California, San Francisco. Many presentations spawn companion papers authored by investigators from Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic, and global collaborators from University of Oxford and Karolinska Institutet.

Attendance and Demographics

Attendees include medical oncologists, surgical oncologists, radiation oncologists, nurse practitioners, physician assistants, researchers, and patient advocates from diverse institutions such as Johns Hopkins Hospital, Cleveland Clinic, and international centers like Royal Marsden Hospital and Peter MacCallum Cancer Centre. Attendance has ranged from tens of thousands, with registrants from countries including the United Kingdom, Canada, Japan, Australia, and Germany. Demographic analyses presented at the meeting often involve multicenter cohorts from consortia like SWOG, EORTC, and Alliance for Clinical Trials in Oncology and highlight contributors from academic departments at Harvard Medical School and University of Toronto.

Controversies and Criticisms

Criticisms have included concerns about conflicts of interest involving industry funding from firms such as Roche, Pfizer, and Bristol Myers Squibb and disclosure practices similar to debates at other meetings like European Society for Medical Oncology congresses. Debate has arisen over the interpretation of early-phase data leading to premature practice changes, as occurred following presentations tied to agents developed by Genentech and Merck & Co.. Additional controversies have focused on access and equity issues affecting patients represented by advocacy groups like Susan G. Komen and policy debates involving agencies such as the Centers for Medicare & Medicaid Services.

Notable Presentations and Breakthroughs

The meeting has showcased pivotal trials and translational advances, including immunotherapy trials associated with investigators from University of California, Los Angeles, Memorial Sloan Kettering Cancer Center, and companies like Merck & Co. (checkpoint inhibitors) and Bristol Myers Squibb (combination regimens). Landmark presentations have included targeted therapy data from teams at Dana-Farber Cancer Institute and Massachusetts General Hospital leading to approvals by the Food and Drug Administration and guideline incorporation by the National Comprehensive Cancer Network. Hematologic oncology breakthroughs have involved researchers from Fred Hutchinson Cancer Research Center and Stanford University School of Medicine with cellular therapies influenced by work at University of Pennsylvania Perelman School of Medicine and biotech firms such as Novartis.

Category:Medical conferences